Relmada Therapeutics is an institution that offers specialized therapies for individuals suffering from chronic pain. The clinical stage company is found in the US, and its products are used in different parts of the globe. Relmada Therapeutics recently went to court to sue an investment company (Laidlaw). According to the pharmaceutical firm, the Laidlaw and Company had breached a contract signed in the past. The US District Court of Nevada reviewed the case and decided to issue an associate injunction and restraining order to the investment firm and its two principles.
By granting the injunction and associate injunction, the court will have Laidlaw and its two principles from spreading misleading information about the pharmaceutical firm. Mathew Either and James Ahern are the two principles of the investment institution, and they have been involved in spreading false information and proxy materials from Relmada Therapeutics.
The U.S District Court order is a sign of relief for Relmada Therapeutics. In the recent past, Mathew and James had breached a contract signed years ago. The company had also been involved in disseminating false information that was considered to be misleading to the general public. This information was ruining the reputation of the pharmaceutical firm. According to Laidlaw reports, they had the full rights to control the pharmaceutical company. Relmada Therapeutics had denied these claims, saying that they are false.
Laidlaw Company is an investment company in the United States. The institution is very popular. However, in the recent past, it has had to deal with numerous court cases and complaints from clients who were served in the past. In most of the complaints from the unsatisfied customers, the company violates the financial regulations. These problems have led to regulatory sanctions, monetary penalties, and other problems. The reputation of the company has been damaged by these complaints and court cases from the public.